Please login to the form below
Aplidin
This page shows the latest Aplidin news and features for those working in and with pharma, biotech and healthcare.
ViiV’s two-drug HIV combo backed by CHMP
abaloparatide) and confirming its earlier rejection of Pharma Mar’s Aplidin (plitidepsin) as a treatment for multiple myeloma.
Latest news
-
Promising new agents for multiple myeloma
Other anti-cancer agents. Plitidepsin (Aplidin; PharmaMar) induces cell death through various cellular pathways.
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Featured jobs
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Business Unit Head, Medical Communications, London
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- MaxCyte gets green light for solid tumour cell therapy
- Brexit rebels win vote on European Medicines Agency alignment
- Positive mid-stage trial gives Allergy’s investors some welcome relief
- Random42 win Creativity International Award for Scientific Animation
- Merck & Co joins big pharma pricing pledge – but sceptics unconvinced
- Aurora partners with PIPHealth and taps into patient panels
- FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics
- Allergan’s abicipar matches AMD blockbuster Lucentis in phase III
- OUTiCO growth in multi-channel creates more job openings
PMHub
OUTiCO
Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
